OMFS IMPATH Research Group, Faculty of Medicine, Department of Imaging and Pathology , University of Leuven, Leuven, Belgium.
Oral and Maxillofacial Surgery, University Hospitals Leuven, Leuven, Belgium.
J Periodontal Res. 2020 Oct;55(5):686-693. doi: 10.1111/jre.12755. Epub 2020 May 14.
Little is known about structural and mechanical properties of leukocyte- and platelet-rich fibrin (L-PRF) membranes and even less about the influence of antithrombotic drugs on L-PRF. The aim of this in vitro study is therefore to investigate mechanical properties, fibrin structure and cell content of L-PRF membranes and the impact of anticoagulant therapy on L-PRF.
Blood samples were obtained from 12 volunteers and supplemented with either no, 1.25 IU, 2.5 IU, 5 IU, or 10 IU enoxaparin. L-PRF membranes were characterized with tensile testing, scanning electron microscopy, and measurement of platelets and leukocytes. Control and enoxaparin-supplemented L-PRF membranes were compared.
At 10 IU enoxaparin, no L-PRF membranes could be generated, whereas the low doses of 1.25 and 2.5 IU had no influence on L-PRF properties. The mechanical properties, fibrin networks, and number of platelets and leukocytes of 5 IU supplemented membranes were unlike the control membranes, but were not found to be significantly different because of limited sampling and inter- and intra-variability.
Low doses of the anticoagulant enoxaparin do not affect mechanical properties, fibrin network, nor cellular content of L-PRF, whereas high doses impair L-PRF generation.
关于富含白细胞和血小板的纤维蛋白(L-PRF)膜的结构和力学性能知之甚少,关于抗血栓药物对 L-PRF 的影响则更少。因此,本体外研究旨在研究 L-PRF 膜的力学性能、纤维蛋白结构和细胞含量,以及抗凝治疗对 L-PRF 的影响。
从 12 名志愿者中抽取血液样本,并分别添加 0、1.25 IU、2.5 IU、5 IU 或 10 IU 的依诺肝素。通过拉伸试验、扫描电子显微镜和血小板及白细胞计数对 L-PRF 膜进行表征。比较对照组和依诺肝素添加组的 L-PRF 膜。
当依诺肝素剂量为 10 IU 时,无法生成 L-PRF 膜,而低剂量的 1.25 和 2.5 IU 对 L-PRF 性能没有影响。添加 5 IU 依诺肝素的 L-PRF 膜的力学性能、纤维蛋白网络以及血小板和白细胞数量与对照组不同,但由于样本有限以及个体间和个体内的变异性,这些差异没有达到显著水平。
低剂量的抗凝剂依诺肝素不会影响 L-PRF 的力学性能、纤维蛋白网络或细胞含量,而高剂量会影响 L-PRF 的生成。